ST. PAUL — Minnesota’s share of a $71 million multistate settlement with biotech drugmaker Amgen tops $1.2 million.

The deal to end an investigation into illegal marketing of two drugs made by the company was announced earlier this week. Court papers filed in Minnesota said the state’s portion will go toward individuals who experienced harm, administrative costs and the general treasury if any is left.

Forty-eight states and Washington D.C. reached the agreement with Amgen, the maker of drugs to treat anemia in cancer patients and ailments like plaque psoriasis.

The company said the settlement isn’t an admission of guilt or wrongdoing.